Journal
CURRENT DRUG METABOLISM
Volume 18, Issue 9, Pages 808-813Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389200218666170203110135
Keywords
Alzheimer's disease; amyloid beta; amyloid precursor protein; apolipoprotein; tau; therapeutics
Ask authors/readers for more resources
Background: Alzheimer's disease (AD) is an irreversible multifaceted neurodegenerative disorder that gradually degrades neuronal cells. It is the most frequent cause of memory loss and dementia in elderly individuals worldwide. The extracellular deposition of beta amyloid (A beta), intracellular neurofibrillary tangles (NFTs) retention, neuronal decline and neurotransmitter system derangement are the patho-physiological marker of this devastated disease. Objective: In view of limited treatment option and their success rate, there is an urgent need to explore the vast array of proteomes for the management of AD. These proteins could be therapeutically targeted to prevent the progression of this disease. In the present review, we tried to uncover several proteins that could be exploited in AD therapeutics. Conclusion: Based on our article, we conclude that proteome based AD treatment needs more refinements and approaches to achieve the desired success rate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available